1. Home
  2. ALHC vs INDV Comparison

ALHC vs INDV Comparison

Compare ALHC & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alignment Healthcare Inc.

ALHC

Alignment Healthcare Inc.

HOLD

Current Price

$21.43

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Indivior PLC

INDV

Indivior PLC

HOLD

Current Price

$32.56

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALHC
INDV
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.7B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
ALHC
INDV
Price
$21.43
$32.56
Analyst Decision
Buy
Analyst Count
8
0
Target Price
$23.13
N/A
AVG Volume (30 Days)
3.0M
1.8M
Earning Date
04-30-2026
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
8100.00
EPS
N/A
1.64
Revenue
$3,948,719,000.00
$1,239,000,000.00
Revenue This Year
$33.69
N/A
Revenue Next Year
$24.74
N/A
P/E Ratio
$405.00
$19.95
Revenue Growth
46.06
4.29
52 Week Low
$11.63
$8.69
52 Week High
$23.87
$38.00

Technical Indicators

Market Signals
Indicator
ALHC
INDV
Relative Strength Index (RSI) 64.20 54.69
Support Level $19.93 $31.70
Resistance Level $23.31 $35.75
Average True Range (ATR) 0.88 1.25
MACD 0.26 0.30
Stochastic Oscillator 79.35 74.01

Price Performance

Historical Comparison
ALHC
INDV

About ALHC Alignment Healthcare Inc.

Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.

About INDV Indivior PLC

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Share on Social Networks: